top of page

Biobeat was included as Top 10 M&A targets in Medtech

Updated: Dec 31, 2023

Biobeat have been included in Fierce Biotech’s list of top M&A targets in Medtech, showing the benefits of Biobeat, and its advantage over other players in the wearable monitoring space, with the huge advantage of continuous blood pressure monitoring.

Fierce Biotech's recognition highlights Biobeat's exceptional value proposition, setting it apart from others in the wearable monitoring landscape. The article emphasizes the distinctive advantage of Biobeat's technology: its ability to continuously monitor blood pressure. This feature is a game-changer in healthcare, offering real-time insights into cardiovascular health and enabling timely interventions.

By being featured in this prestigious list, Biobeat gains visibility as an attractive investment opportunity within the Medtech sector. The acknowledgment of its potential as a top M&A target is a testament to the company's innovative approach and the impact its technology can have on patient care and monitoring.

In essence, Biobeat's inclusion in Fierce Biotech's list signals its recognition as a standout player in the wearable monitoring field, particularly due to its continuous blood pressure monitoring capability. This achievement serves as a reflection of Biobeat's industry-leading advancements and positions it as a potential frontrunner in future Medtech developments and partnerships.



bottom of page